BenchSci
PrivateLast Round
Series D
May 25, 2023
Total Funding Raised
$159.94M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
BenchSci is a biotechnology company that offers a research intelligence platform leveraging machine learning and artificial intelligence to optimize antibody extraction experiments, helping researchers accelerate biomedical discoveries efficiently.
Sector
Healthcare & Life Sciences
Verticals
Drug Discovery, Biotechnology, Medical AI, Healthcare Analytics
Business Model
B2B
Customer Profile
Subscription SaaS, Services & Consulting
AI Layer
Application
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
BenchSci Comparables
Compare BenchSci with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Insilico Medicine | 87% | |
| Causaly | 85% | |
| Biorelate | 78% |
BenchSci Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series D | May 25, 2023 | ||||
| Series C | Jan 24, 2022 | ||||
| Series B | Feb 4, 2020 | ||||
| Series A Extension | Jun 25, 2019 | ||||
| Series A | May 2, 2018 | ||||
Seed | Jul 1, 2017 |
BenchSci Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Gradient Ventures | Series B, Series A, Series D, Series C, Series A Extension |
| Northleaf Capital Partners | Series B, Series C |
| Fidelity Investments Canada ULC | Series D, Series C, Series B |
| TCV | Series D, Series C |
| Inovia Capital | Series B, Series D, Series A Extension, Series A, Series C |
| F-Prime Capital | Series D, Series C, Series B |
| Creative Destruction Lab | Pre Seed |
Market signals
Structured signals derived from secondary market and firmographic data.
- Apr 21, 2026
Achieved 247% growth over three years, recognized by Deloitte.
- Apr 21, 2026
Platform used by 9 of top 10 pharma companies across 4,500+ research centers.
Recent news
Latest coverage and updates
- partners_withSep 2, 2026
BenchSci partnered with Argenx on Sep 2nd '26.
BenchSci Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about BenchSci's valuation, stock price, and market status.
Is Benchsci a public or private company?
Benchsci is a private company.
What is the current stock price of Benchsci?
Benchsci is a private company with no public stock price. No recent secondary market data is available.
How much is Benchsci worth (valuation)?
Valuation information for Benchsci is not publicly available.
Can I buy Benchsci stock?
Benchsci shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was Benchsci's last funding round?
Benchsci's most recent funding round was Series D on May 25, 2023.
Who are the main investors in Benchsci?
Key investors in Benchsci include Gradient Ventures, Fidelity Investments Canada, TCV, Inovia Capital, F-Prime Capital.
Will Benchsci IPO soon?
No public IPO plans have been announced for Benchsci.
How can I track Benchsci secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Benchsci's secondary market activity and sign up for updates.